Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) (Aug, 10.1007/s12282-024-01614-1, 2024)

被引：0

作者：

Nakayama, Takahiro ^{[1
]}

Niikura, Naoki ^{[2
]}

Yamanaka, Takashi ^{[3
]}

Yamamoto, Mitsugu ^{[4
]}

Matsuura, Kazuo ^{[5
]}

Inoue, Kenichi ^{[6
]}

Takahara, Sachiko ^{[7
]}

Nomura, Hironori ^{[8
]}

Kita, Shosuke ^{[9
]}

Yamaguchi, Miki ^{[10
]}

Aruga, Tomoyuki ^{[11
]}

Shibata, Nobuhiro ^{[12
]}

Shimomura, Akihiko ^{[13
]}

Ozaki, Yuri ^{[14
]}

Sakai, Shuji ^{[15
]}

Takiguchi, Daisuke ^{[16
]}

Takata, Takehiko ^{[16
]}

Bastanfard, Armin ^{[16
]}

Shiosakai, Kazuhito ^{[17
]}

Tsurutani, Junji ^{[18
]}

机构：

[1] Osaka Int Canc Inst, Dept Breast & Endocrine Surg, Osaka, Japan

[2] Tokai Univ, Dept Breast Oncol, Sch Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan

[3] Kanagawa Canc Ctr, Dept Breast Surg & Oncol, Yokohama, Kanagawa, Japan

[4] Hokkaido Canc Ctr, Dept Breast Oncol, Sapporo, Hokkaido, Japan

[5] Saitama Med Univ, Int Med Ctr, Dept Breast Oncol, Saitama, Japan

[6] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan

[7] Kitano Hosp, Dept Breast Surg, Osaka, Japan

[8] Univ Ryukyus Hosp, Dept Surg 1, Nishihara, Okinawa, Japan

[9] Natl Canc Ctr, Dept Med Oncol, Tokyo, Japan

[10] JCHO Kurume Gen Hosp, Dept Breast Surg, Fukuoka, Japan

[11] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Breast Surg, Tokyo, Japan

[12] Kansai Med Univ Hosp, Canc Treatment Ctr, Osaka, Japan

[13] Natl Ctr Global Hlth & Med, Dept Breast & Med Oncol, Tokyo, Japan

[14] Aichi Canc Ctr, Dept Breast Oncol, Aichi, Japan

[15] Tokyo Womens Med Univ, Dept Diagnost Imaging & Nucl Med, Tokyo, Japan

[16] Daiichi Sankyo Co Ltd, Oncol Med Sci Dept 1, Tokyo, Japan

[17] Daiichi Sankyo Co Ltd, Data Intelligence Dept, Tokyo, Japan

[18] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan

来源：

BREAST CANCER | 2024年 / 31卷 / 06期

关键词：

Brain metastasis; Breast cancer; HER2+; Leptomeningeal; Trastuzumab deruxtecan;

D O I：

10.1007/s12282-024-01632-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We provide updated results (median follow-up duration: 20.4 months) of a retrospective study on the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer with brain metastases (BM) and/or leptomeningeal disease (ROSET-BM). Median progression-free survival (PFS) was 14.6 months. Median overall survival (OS) was not reached (NR); 24-month OS rate was 56.0%. Subgroup analysis showed that median PFS was 13.2 months in patients with analytical active BM, 17.5 months in patients with leptomeningeal carcinomatosis (LMC), and NR in patients with analytical stable BM (24-month PFS rates in patients with analytical active BM, LMC, and analytical stable BM were 32.7%, 25.1%, and 60.8%, respectively). Median OS was 27.0 months in patients with analytical active BM and NR in patients with LMC or analytical stable BM (24-month OS rates in patients with analytical active BM, LMC, and analytical stable BM were 52.0%, 61.6%, and 71.6%, respectively). The most common adverse event leading to discontinuation of T-DXd was interstitial lung disease (ILD; 23.1%); median ILD onset time among patients who discontinued T-DXd treatment due to ILD was 5.3 months. T-DXd has promising effectiveness in heavily pre-treated HER2+ metastatic breast cancer patients with BM and LMC. The incidence and median onset time of ILD were similar to those of Japanese subgroups in previous studies.

引用

页码：1184 / 1184

页数：1